A DOUBLE-BLIND CROSS-OVER CONTROLLED-STUDY TO EVALUATE THE EFFECT OF HUMAN BIOSYNTHETIC GROWTH-HORMONE ON OVARIAN STIMULATION IN PREVIOUS POOR RESPONDERS TO IN-VITRO FERTILIZATION
Sm. Hughes et al., A DOUBLE-BLIND CROSS-OVER CONTROLLED-STUDY TO EVALUATE THE EFFECT OF HUMAN BIOSYNTHETIC GROWTH-HORMONE ON OVARIAN STIMULATION IN PREVIOUS POOR RESPONDERS TO IN-VITRO FERTILIZATION, Human reproduction, 9(1), 1994, pp. 13-18
The effect of exogenous human biosynthetic growth hormone (HGH; 12 IU/
day; Norditropin, Novo-Nordisk) on the response to ovarian stimulation
using a buserelin/human menopausal gonadotrophin (HMG) regimen was as
sessed in women who had previously shown a 'poor response' in spite of
increasing doses of HMG. Forty patients were recruited into a prospec
tive double-blind placebo-controlled study. The serum follicle stimula
ting hormone (FSH) on day 2-5 of a menstrual cycle (<10 IU/l) was used
to exclude any peri-menopausal candidates. The urinary 24 h GH secret
ion was normal in all patients. Thirty-three patients completed the st
udy with 21 patients having human chorionic gonadotrophin (HCG) in bot
h arms, thus providing a complete set of placebo control data. Of thes
e 21 patients, the administration of HGH compared to the placebo cycle
resulted in increased serum concentrations of fasting insulin on the
8th (median 3.9 versus 5.8 mU/l; P < 0.0005) and 13th (median 4.4 vers
us 5.8 mU/l; P < 0.05) day of HMG in those cycles receiving HGH. After
8 days of co-treatment with HGH the number of cohort follicles (14-16
.9 mm) was significantly increased, but this change was not sustained
on the day of HCG administration. No statistical difference in the ser
um oestradiol on the 8th day of HMG or day of HCG, length of the folli
cular phase, total dose of HMG used, or the number of oocytes collecte
d was seen between the placebo or HGH cycles. This study demonstrates
that HGH does not improve the ovarian response to ovulation induction
in previous poor responders.